Matteo Augugliaro
Overview
Explore the profile of Matteo Augugliaro including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
31
Citations
174
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Francolini G, Bertini N, Di Cataldo V, Garlatti P, Aquilano M, Caini S, et al.
Prostate Cancer Prostatic Dis
. 2025 Feb;
PMID: 39972049
ARTO trial was a phase II randomized trial suggesting the benefit of a concomitant treatment strategy including Abiraterone acetate plus predisone (AAP) and stereotactic body radiotherapy (SBRT) in oligometastatic castrate...
2.
Iori F, Augugliaro M, Ali E, Iotti C
Clin Transl Radiat Oncol
. 2025 Jan;
51():100909.
PMID: 39845564
The role of elective pelvic nodal irradiation (EPNI) for high-risk prostate cancer (hrPC) management is still an open issue, especially for the elderly patients. It is unclear whether older patients...
3.
Francolini G, Allegra A, Detti B, Di Cataldo V, Caini S, Bruni A, et al.
J Clin Oncol
. 2023 Sep;
41(36):5561-5568.
PMID: 37733977
Purpose: ARTO (ClinicalTrials.gov identifier: NCT03449719) is a multicenter, phase II randomized clinical trial testing the benefit of adding stereotactic body radiation therapy (SBRT) to abiraterone acetate and prednisone (AAP) in...
4.
Cozzi S, Ruggieri M, Ali E, Finocchi Ghersi S, Vigo F, Augugliaro M, et al.
In Vivo
. 2023 Mar;
37(2):777-785.
PMID: 36881094
Background/aim: Radiotherapy represents an important therapeutic option in the management of prostate cancer (PCa). As helical tomotherapy may improve toxicity outcomes, we aimed to evaluate and report the toxicity and...
5.
Cozzi S, Finocchi Ghersi S, Bardoscia L, Najafi M, Blandino G, Ali E, et al.
Strahlenther Onkol
. 2023 Feb;
199(6):554-564.
PMID: 36732443
Background: The rates of local failure after curative radiotherapy for prostate cancer (PC) remain high despite more accurate locoregional treatments available, with one third of patients experiencing biochemical failure and...
6.
Cozzi S, Ali E, Bardoscia L, Najafi M, Botti A, Blandino G, et al.
Cancers (Basel)
. 2022 Jun;
14(11).
PMID: 35681659
Introduction: Mediastinal or hilar lymph node metastases are a challenging condition in patients affected by solid tumors. Stereotactic body radiation therapy (SBRT) could play a crucial role in the therapeutic...
7.
Cozzi S, Augugliaro M, Ciammella P, Botti A, Trojani V, Najafi M, et al.
Cancers (Basel)
. 2022 May;
14(10).
PMID: 35626168
Breast cancer represents the second leading cause of cancer-related death in the female population, despite continuing advances in treatment options that have significantly accelerated in recent years. Conservative treatments have...
8.
Cozzi S, Bardoscia L, Najafi M, Botti A, Blandino G, Augugliaro M, et al.
Curr Oncol
. 2022 Mar;
29(3):1866-1876.
PMID: 35323352
Adenoid cystic carcinoma/basaloid cell carcinoma of the prostate (ACC/BCC) is a very rare variant of prostate cancer with uncertain behavior. Few cases are reported in the literature. Data on treatment...
9.
Marvaso G, Volpe S, Pepa M, Zaffaroni M, Corrao G, Augugliaro M, et al.
Cancer Manag Res
. 2022 Jan;
14:89-101.
PMID: 35023972
After primary treatment for prostate cancer with either radical prostatectomy or radiotherapy, a significant proportion of patients are at risk of developing metastases. In recent years, a deeper understanding of...
10.
Corrao G, Marvaso G, Zaffaroni M, Volpe S, Augugliaro M, Fodor C, et al.
Neoplasma
. 2022 Jan;
69(2):404-411.
PMID: 35014537
PTEN deletion and Ki-67 expression are two of the most promising biomarkers in prostate cancer (PCa). In the same manner, multiparametric magnetic resonance imaging (mp-MRI) guided core biopsy is a...